AG-CR1-0160-M0055 mgCHF 90.00
AG-CR1-0160-M02525 mgCHF 270.00
|Purity Chemicals||≥98% (HPLC)|
|Appearance||Off-white to tan solid.|
|Solubility||Soluble in DMSO (2mg/ml), ethanol or methanol. Insoluble in water.|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Keep cool and dry.|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- Specific competitive RIPK1 inhibitor in vitro (IC50=1.03µM). Binds to human RIPK1 adenosine triphosphate-binding site and locks it in an inactive conformation to block necroptosis. Necroptosis contributes to the pathogenesis of several inflammatory diseases including ischemic reperfusion injury, acute pancreatitis, sepsis, neurodegeneration, viral infection and liver diseases.
- Inhibits both TNF-induced RIPK1-dependent necroptosis and RIPK1-dependent apoptosis in FADD-deficient Jurkat cells (EC50=1.2µM). Does not block caspase-dependent apoptosis induced by TRAIL, FasL or staurosporine.
- Protects mice from concanavalin A-induced hepatitis in vivo.
- Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis: F. Le Cann, et al.; FEBS J. 284, 3050 (2017)